Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-PeriOp GC: Novel Agents as Perioperative Treatment in Resectable Gastroesophageal Adenocarcinoma
NCT07069712Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 11
01
Overview
A Phase 2 trial of sonesitatug vedotin, rilvegostomig, trastuzumab deruxtecan in gastroesophageal adenocarcinoma, sponsored by AstraZeneca. Started Jul 2025; status: recruiting.
02
Drugs
sonesitatug vedotinrilvegostomigtrastuzumab deruxtecan
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT07069712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069712.